Natriuretic peptide assessment serves as an important and necessary tool for diagnosis, risk stratification, and individualized treatment in routine heart failure outpatient management.
Natriuretic peptide assessment is a crucial tool for diagnosing, risk-stratifying, and tailoring treatment for heart failure patients in outpatient settings.
In many European countries, patients with heart failure (HF) are treated according to specific management programs. The key players are the HF cardiologists and the HF nurses, and they are supported by a number of other important players. The objectives of the HF team are to help verify the diagnosis, optimize treatment, and inform and educate the patients and their relatives to achieve beneficial effects in terms of improved survival, less hospitalization, and improved quality of life. The use of natriuretic peptides (NPs) helps the referring physician correctly diagnose and select patients for further investigations. Based on the levels of NPs, it is possible to risk-stratify patients and offer them individualized, tailored treatment. The present paper discusses and exemplifies how NP assessment may be integrated into an HF outpatient program. Our conclusion is that NP values will continue to be important and necessary tools in the routine management of patients with HF.
Dahlström et al. (Tue,) conducted a review in Heart failure. Natriuretic peptide (NP) assessment was evaluated. Natriuretic peptide assessment serves as an important and necessary tool for diagnosis, risk stratification, and individualized treatment in routine heart failure outpatient management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: